TITLE:
Evaluating the Influence of the Prostate Weight on the Morbidity and Mortality of Transvesical Open Prostatectomy: Prospective Analysis of 108 Cases in the Urology-Andrology Department of the Ignace Deen National Hospital in Conakry
AUTHORS:
Thierno Oumar Diallo, Alimou Diallo, Alpha Oumar Barry, Thierno Mamadou Oury Diallo, Alseny Bah, Youssouf Keita, Daouda Kanté, Mamadou Bissiriou Bah, Demba Cissé, Ibrahima Bah, Abdoulaye Bobo Diallo, Oumar Raphiou Bah
KEYWORDS:
Benign Prostatic Hyperplasia (BPH), Adenomectomy, Prostate Weight, Complication
JOURNAL NAME:
Open Journal of Urology,
Vol.14 No.4,
April
29,
2024
ABSTRACT: Introduction: Open transvesical prostatectomy remains today one of the most effective approaches for the management of benign prostatic hyperplasia despite the fact that, this method is associated with multiple complications. The objective of this study was to evaluate the influence of prostate weight on the morbidity and mortality of transvesical prostatectomy for adenoma in the urology-andrology department of the Ignace Deen National Hospital. Materials and Methods: This was a prospective, longitudinal and analytical study lasting 6 months, from March 1, 2022 to August 31, 2022 including patients admitted and operated on by open transvesical prostatectomy by assessing the influence of prostate weight on the morbidity and mortality of transvesical adenomectomies. Results: 108 patients were included in our study, the average age of our patients was 70 ± 7.7 years, cultivators were the most represented profession with 38.89%, and hypertension was the most represented comorbidity with 75%. 33.06% of cases became complicated and surgical wound infection was the main complication with a frequency of 17.40%. Statistical analysis did not conclude that, the prostate weight does not have a statistically significant influence on the morbidity and mortality of transvesical open prostatectomy for benign prostatic hyperplasia. Conclusion: Prostate weight has no influence on the morbidity and mortality of transvesical prostate adenoma.